{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241845","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.054903+00:00","generated_at":"2026-06-10T08:39:29.722050+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Soleno reports positive Phase 3 results for DCCR in Prader-Willi; primary endpoint met (p=0.0022)","bullets":["Primary endpoint: HQ-CT total score difference of 5.0 at week 16 (p=0.0022) favoring DCCR over placebo.","Secondary endpoints (CGI-S, CGI-I) showed trends toward worsening in placebo group (p=0.08 and 0.09).","DCCR well-tolerated; no serious adverse events or discontinuations in DCCR group.","Positive data triggers $15M warrant exercise (8.6M shares at $1.75) within 30 days by Nantahala, Abingworth, Vivo.","Company targets NDA submission for DCCR in PWS mid-2024; FDA previously acknowledged potential for NDA support."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241845","json":"https://secwatch.observer/filing/0001193125-23-241845.json","markdown":"https://secwatch.observer/filing/0001193125-23-241845.md","text":"https://secwatch.observer/filing/0001193125-23-241845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523241845/0001193125-23-241845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523241845/d486361d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:39:29.722050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}